Table 2.

CR in AML in elderly patients by treatment arm and by stratification factors age and disease status


Characteristic

DNR/Ara-C

DNR/Ara-C + PSC-833

Total
Total   101/211; 48% (41%-55%)   112/208; 54% (47%-61%)   213/419; 51% (46%-56%)  
Age, y    
    58-65   43/77; 56% (44%-67%)   53/77; 69% (57%-79%)   96/154; 62% (54%-70%)  
    66-70   36/71; 51% (39%-63%)   33/69; 48% (36%-60%)   69/140; 49% (41%-58%)  
    71-85   22/63; 35% (23%-48%)   26/62; 42% (30%-55%)   48/125; 38% (30%-48%)  
Secondary AML    
    No   79/155; 51% (43%-59%)   95/160; 59% (51%-67%)   174/315; 55% (50%-61%)  
    Yes
 
22/56; 39% (26%-53%)
 
17/48; 35% (22%-51%)
 
39/104; 38% (28%-48%)
 

Characteristic

DNR/Ara-C

DNR/Ara-C + PSC-833

Total
Total   101/211; 48% (41%-55%)   112/208; 54% (47%-61%)   213/419; 51% (46%-56%)  
Age, y    
    58-65   43/77; 56% (44%-67%)   53/77; 69% (57%-79%)   96/154; 62% (54%-70%)  
    66-70   36/71; 51% (39%-63%)   33/69; 48% (36%-60%)   69/140; 49% (41%-58%)  
    71-85   22/63; 35% (23%-48%)   26/62; 42% (30%-55%)   48/125; 38% (30%-48%)  
Secondary AML    
    No   79/155; 51% (43%-59%)   95/160; 59% (51%-67%)   174/315; 55% (50%-61%)  
    Yes
 
22/56; 39% (26%-53%)
 
17/48; 35% (22%-51%)
 
39/104; 38% (28%-48%)
 

Each cell contains the number of CR patients followed by the number of patients in the specific subgroup and the corresponding percentage, with its 95% CI.

Close Modal

or Create an Account

Close Modal
Close Modal